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P-Type Natriuretic Peptide, a Novel
ntifibrotic and Antihypertrophic Agent,
revents Cardiac Remodeling After Myocardial Infarction
akeshi Soeki, MD,* Ichiro Kishimoto, MD,* Hiroyuki Okumura, MD,* Takeshi Tokudome, MD,*
akeshi Horio, MD,† Kenji Mori, PHD,* Kenji Kangawa, PHD*
uita, Osaka, Japan
OBJECTIVES We assessed the hypothesis that in vivo administration of C-type natriuretic peptide (CNP)
might attenuate cardiac remodeling after myocardial infarction (MI) through its antifibrotic
and antihypertrophic action.
BACKGROUND Recently, we have shown that CNP has more potent antifibrotic and antihypertrophic effects
than atrial natriuretic peptide (ANP) in cultured cardiac fibroblasts and cardiomyocytes.
METHODS Experimental MI was induced by coronary ligation in male Sprague-Dawley rats; CNP at 0.1
g/kg/min (n  34) or vehicle (n  35) was intravenously infused by osmotic mini-pump
starting four days after MI. Sham-operated rats (n  34) served as controls. After two weeks
of infusion, the effects of CNP on cardiac remodeling were evaluated by echocardiograpic,
hemodynamic, histopathologic, and gene analysis.
RESULTS C-type natriuretic peptide markedly attenuated the left ventricular (LV) enlargement caused
by MI (LV end-diastolic dimension, sham: 6.7  0.1 mm; MIvehicle; 8.3  0.1 mm;
MICNP: 7.7  0.1 mm, p  0.01) without affecting arterial pressure. Moreover, there was
a substantial decrease in LV end-diastolic pressure, and increases in dP/dtmax, dP/dtmin, and
cardiac output in CNP-treated MI rats compared with vehicle-treated MI rats. Importantly,
CNP infusion markedly attenuated an increase in morphometrical collagen volume fraction
in the noninfarct region (sham: 3.1  0.2%; MIvehicle: 5.7  0.5%; MICNP: 3.9 
0.3%, p  0.01). In addition, CNP significantly reduced an increase in cross-sectional area of
the cardiomyocytes. These effects of CNP were accompanied by suppression of MI-induced
increases in collagen I, collagen III, ANP, and -myosin heavy chain messenger ribonucleic
acid levels in the noninfarct region.
CONCLUSIONS These data suggest that CNP may be useful as a novel antiremodeling agent. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.067Cardiol 2005;45:608–16) © 2005 by the American College of Cardiology Foundation
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ahe mammalian natriuretic peptide system consists of three
tructurally homologous peptides, atrial natriuretic peptide
ANP), brain natriuretic peptide (BNP), and C-type natri-
retic peptide (CNP) (1). The actions of the natriuretic
eptides are modulated through membrane-bound recep-
ors, two of which are guanylyl cyclase (GC)-coupled
eceptors (GC-A and GC-B). These receptors are linked to
he cyclic guanosine monophosphate (cGMP)-dependent
ignaling cascade and mediate the biological actions of the
eptides (2). Atrial natriuretic peptide and BNP are mainly
eleased from the heart to act as circulating hormones,
hich bind to their specific receptor, GC-A, in the vascular
issue, kidney, and adrenal gland and induce vasodilation,
atriuresis, and diuresis (3). C-type natriuretic peptide,
hich was originally isolated from porcine brain extracts (4),
ot only acts in the central nervous system, but also plays a
ole in the local regulation such as the suppression of
eointimal formation after vascular injury (5) through its
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ccepted October 25, 2004.pecific receptor, GC-B. Recently, we have shown that
NP was synthesized in cultured cardiac fibroblasts and
hat CNP inhibited both deoxyribonucleic acid (DNA) and
ollagen synthesis of cardiac fibroblasts more potently than
NP and BNP (6). C-type natriuretic peptide also has more
otent antihypertrophic effects than ANP in cultured car-
iomyocytes (7). These findings might be due to the relative
bundance of GC-B over GC-A in cardiac fibroblasts and
n cardiomyocytes (6,7). In addition, in a recent clinical
tudy, CNP was produced by the hearts of patients with
hronic heart failure, and its level in the coronary sinus
orrelated with mean pulmonary wedge pressure (8). These
asic and clinical results suggest that CNP might represent
n important local mediator in the heart.
Left ventricular (LV) remodeling after myocardial infarc-
ion (MI) is a major cause of subsequent heart failure and
eath (9). Postinfarction remodeling has been divided into
n early phase (within 72 h), which involves expansion of
he infarct zone, and a late phase (after 72 h), which is
ssociated with time-dependent LV dilation, mural hyper-
rophy, and cardiac fibrosis (10). Given the inhibitory effects
f CNP on cardiac fibrosis and hypertrophy in vitro, CNP
ight act against the progression of cardiac late remodeling
fter MI. Furthermore, because intravenously administered
NP has been demonstrated to have much less potent
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February 15, 2005:608–16 CNP and Cardiac Remodeling After MIasorelaxant and natriuretic activities than ANP (4,11),
NP is not expected to perturb systemic hemodynamics
fter massive MI while ANP or BNP is. However, there has
een no in vivo evidence to directly prove these beneficial
ffects of CNP after MI. Therefore, in the present study, we
ave assessed the hypothesis that in vivo administration of
NP might attenuate cardiac late remodeling after MI. In
ddition, to elucidate the mechanism involved in the anti-
brotic action of CNP, we investigated the action of
GMP/cGMP-dependent protein kinase (PKG) pathway
n collagen synthesis by cardiac fibroblasts in vitro, and to
larify whether CNP is an important local mediator in the
eart, we investigated the degree and source of endogenous
NP production in the infarcted heart.
ETHODS
odel of MI. All experimental procedures were performed
ccording to the guidelines for animal experimentation of
ational Cardiovascular Center. Male Sprague-Dawley rats
Nihon SLC, Hamamatsu, Japan) weighing 180 to 220 g
ere anesthetized with sodium pentobarbital (30 mg/kg,
ntraperitoneally). After left thoracotomy, the left coronary
rtery was ligated 2 to 3 mm from its origin using a 6-0
rolene suture. The chest was closed, and the rats were
llowed to recover. Sham-operated rats underwent the
dentical surgical procedure as described above without the
ctual coronary artery ligation.
dministration of CNP. Four days after coronary ligation,
he rats with MI were randomly divided into two groups:
ne to be infused with synthetic CNP (MICNP, n  36)
nd the other with vehicle (MIvehicle, n 42). The CNP
roup was then fitted with subcutaneous osmotic mini-
umps (model 2ML2, Alza Corp., Palo Alto, California)
lled with synthetic CNP dissolved in a 5% glucose solution
nd set to release 0.1 g/kg/min of the peptide for two
eeks. The dose of CNP was chosen because our prelimi-
ary study revealed that CNP at this dose has no effects on
rterial blood pressure and heart rate in rats. Glucose
olution was infused in a similar manner in the control
Abbreviations and Acronyms
ANP  atrial natriuretic peptide
BNP  brain natriuretic peptide
CNP  C-type natriuretic peptide
cGMP  cyclic guanosine monophosphate
GC  guanylyl cyclase
LV  left ventricle/ventricular
MHC  myosin heavy chain
MI  myocardial infarction
PKG  cyclic guanosine monophosphate-dependent
protein kinase
RV  right ventricle/ventricular
TGF  transforming growth factorroup. The pumps were connected to the left jugular vein by apolyethylene catheter. The synthetic CNP was kindly
rovided by Daiichi Suntory Pharma (Tokyo, Japan).
oninvasive blood pressure and pulse rate. Systolic
lood pressure and pulse rate were measured before MI and
ne day, one week, and two weeks after MI by the tail-cuff
ethod without use of anesthesia (Softron, Tokyo, Japan).
chocardiographic and hemodynamic studies. Echocar-
iographic studies were performed using an echocardio-
raphic system equipped with a 15-MHz phased-array
ransducer (SONOS 5500, Hewlett Packard, Andover,
assachusetts) under anesthesia with sodium pentobarbital
30 mg/kg, intraperitoneally) 4 and 18 days after the
xperimental MI or sham operation as described previously
12). Rats with 20% fractional shortening or an early
lling wave (E) velocity to atrial filling wave (A) velocity
atio of 3 in the echocardiographic study performed four
ays after MI were excluded from the study.
Eighteen days after the coronary ligation or sham oper-
tion, hemodynamic studies were performed under anesthe-
ia as previously described (12). After completion of hemo-
ynamic measurements, the hearts were arrested by the
njection of 30 mM potassium chloride through the carotid
rtery, excised, and weighed.
istological examination. After fixation, three cross-
ections through the ventricles were obtained and embedded
n  17 to 19 in each group). Paraffin sections (2 m) were
tained with Masson’s trichrome for measurement of infarct
ize, hematoxylin and eosin for measurement of myocyte
ize, and Sirius red F3BA for determination of collagen
olume fraction. The infarct size was expressed as previously
escribed (13). For the measurement of cardiomyocyte
ross-sectional area and diameter in the noninfarcted LV, a
otal of 30 myocytes sectioned transversely for area and
ongitudinally for diameter at the level of the nucleus were
andomly chosen from each section at 400 magnification,
nd traced. To measure collagen volume fraction, 16 fields
n the border and remote myocardium of the noninfarcted
V and right ventricle (RV) walls per section were scanned
t a magnification of200. The interstitial collagen volume
raction was measured while omitting fibrosis of the perivas-
ular, epi-, and endocardial areas from the study. The
ollagen volume fraction was obtained by calculating the
ean ratio of connective tissue to the total tissue area of all
he measurements of the section. The collagen-positive
reas from all sections were determined by a single investi-
ator who was unaware of the experimental groups.
orthern blot analysis. Total ribonucleic acid (10 g/
ane) was extracted from the RV, noninfarcted LV, and
nfarcted LV (n  10 in each group). Hybridization was
arried out with cDNA probes for rat -1 (type I) collagen,
at -1 (type III) collagen, rat fibronectin, rat transform-
ng growth factor (TGF)--1, rat ANP, and rat
lyceraldehyde-3-phosphate dehydrogenase (GAPDH).
e also used synthetic oligonucleotide probes for the -nd -myosin heavy chain (MHC) messenger ribonucleic
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CNP and Cardiac Remodeling After MI February 15, 2005:608–16cids (mRNA). The band intensity was estimated by a
adioimage analyzer (BAS-5000, Fuji Film, Tokyo, Japan).
ollagen synthesis in vitro. Neonatal cardiac fibroblasts
ere prepared as described previously (14). The effects of
NP and a cGMP analog on collagen synthesis in cardiac
broblasts were evaluated on subconfluent cultures by the
ncorporation of [3H]proline into cells as previously de-
cribed (6). In brief, after the preconditioning period, CNP
ith or without Rp-8-pCPT-cGMP (Calbiochem, San
iego, California), or 8-Bromo cGMP (Sigma, St. Louis,
issouri) was added, and 0.5 Ci of [3H]proline was also
dded. After the cells were incubated for 24 h, the radio-
ctivity of aliquots of the trichloroacetic acid-insoluble
igure 1. Time course of systolic blood pressure (A) and pulse rate (B) in
ham-operated rats (closed triangles) and in rats with myocardial infarc-
ion (MI) before and during infusion of 0.1 g/kg/min C-type natriuretic
eptide (CNP) (closed circles) or vehicle (5% glucose solution) (open
quares). Values are mean SEM. A p value for systolic blood pressure by
wo-way analysis of variance: group 0.001; time course 0.001; group/
ime course interaction 0.001, and a p value for pulse rate by two-way
nalysis of variance: group 0.05; time course 0.001; group/time course
nteraction 0.01. **p  0.01, *p  0.05 compared with the sham-
perated group at same stage by Bonferroni multiple-comparison t test.
PM  beats/min.aterial was determined using a liquid scintillation counter. huantitative reverse transcription-polymerase chain re-
ction. Endogenous mRNA expressions of ventricular
NP were evaluated in rats killed on day 3, 7, and 18 after
I (without CNP treatment) and on day 3 after sham
peration (n  6 in each group) with quantitative reverse
ranscription-polymerase chain reaction using a LightCycler
ystem (Roche Applied Science, Penzberg, Germany) ac-
ording to the manufacturer’s instruction.
mmunohistochemical analysis. Immunohistochemical
tudies were performed to localize endogenous CNP in LV
yocardium after MI. The section on day 7 after MI (in rats
ithout CNP treatment) was stained with goat anti-CNP
ntibody (Santa Cruz Biotechnology, Santa Cruz, California)
ollowed by Alexa-Fluor donkey anti-goat IgG antibody
Molecular Probes, Eugene, Oregon) and stained with
abbit fibronectin antibody (Sigma, St. Louis, Missouri)
ollowed by tetrarhodamine isothiocyanate-conjugated goat
nti-rabbit IgG antibody (DakoCytomation, Glostrup,
enmark).
tatistical analysis. All values are expressed as mean 
EM. Differences among the groups were evaluated by
ne-way analysis of variance and two-way analysis of vari-
nce for repeated measurements, as appropriate. When a
tatistical difference was detected by analysis of variance, the
onferroni method of adjusting for multiple pairwise com-
arisons was used. A value of p  0.05 was considered
tatistically significant.
ESULTS
he effect of CNP on survival rate and infarct size. Among
he MI rats, two of the CNP-infused rats and seven of the
ehicle-infused rats died during the two-week infusion
eriod. The survival rate of the MICNP group (94%) was
able 1. Echocardiographic Parameters
Sham MIVehicle MICNP
th day (before treatment)
AWT diastole, mm 1.2  0.01 1.0  0.01* 1.0  0.01*
PWT diastole, mm 1.3  0.01 1.3  0.01 1.3  0.01
LVDd, mm 6.4  0.1 7.0  0.1* 7.0  0.1*
FS, % 34  1 16  0.3* 15  0.3*
E velocity, cm/s 89  3 102  2* 103  3*
A velocity, cm/s 49  2 18  1* 19  1*
E/A 1.9  0.1 5.8  0.2* 5.6  0.1*
8th day (after treatment)
AWT diastole, mm 1.2  0.01 0.9  0.02* 0.9  0.01*
PWT diastole, mm 1.3  0.01 1.5  0.02* 1.4  0.02*†
LVDd, mm 6.7  0.1 8.3  0.1* 7.7  0.1*†
FS, % 35  1 16  0.4* 18  0.4*†
E velocity, cm/s 88  2 112  3* 102  3*‡
A velocity, cm/s 51  2 19  1* 26  1*†
E/A 1.8  0.05 6.2  0.2* 4.2  0.2*†
alues are mean SEM. *p 0.01 compared with sham-operated group; †p 0.01,
p  0.05 compared with MIvehicle group by analysis of variance and Bonferroni
ultiple-comparison t test.
A  atrial filling wave; AWT  anterior wall thickness; CNP  C-type
atriuretic peptide; E  early filling wave; FS  fractional shortening; LVDd  left
entricular end-diastolic dimensions; MI  myocardial infarction; PWT  posterior
all thickness.igher than that of the MIvehicle group (83%), but this
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February 15, 2005:608–16 CNP and Cardiac Remodeling After MIifference was not statistically significant by Kaplan-Meier
urvival analysis (p 0.13). No rats died in the sham group.
herefore, the total numbers for final analysis were 34 rats
n the MICNP group, 35 in the MIvehicle group, and
4 in the sham group. There was no difference in infarct size
etween the MICNP and MIvehicle groups (45  1%
nd 46  1%, respectively).
erial change of noninvasive blood pressure and pulse
ate. A significant reduction in the systolic blood pressure
as observed in MICNP or MIvehicle rats compared
ith the sham-operation rats during two weeks after the
peration. As shown in Figure 1A, the systolic blood
ressure was not perturbed by CNP infusion at any time
oints. The pulse rate in MI groups significantly increased
t day 1 compared with sham animals and decreased
radually. The pulse rate was not significantly affected by
NP treatment at any time points (Fig. 1B).
he effect of CNP on echocardiographic and hemody-
amic parameters. Table 1 shows echocardiographic as-
essments of cardiac geometry and function for the three
roups of rats at the 4th and 18th days after MI. At the 4th
ay (before CNP infusion), when compared with sham, LV
nlargement, decreased fractional shortening, and increased
atio of E to A velocities were seen in similar degree in both
I groups. At the 18th day (after two weeks of CNP
igure 2. The effect of C-type natriuretic peptide (CNP) infusion on colla
fter myocardial infarction (MI). Representative photomicrographs of co
agnification) (left) and quantitative morphometric analysis (right). Value
0.01 compared with the MIvehicle group by analysis of variance andnfusion), hypertrophy of the posterior wall and the LV
e
aavity enlargement caused by MI were significantly attenu-
ted by CNP infusion, although thinning of the anterior
all was not changed; CNP also ameliorated the decrease of
ractional shortening. Furthermore, CNP significantly im-
roved LV diastolic filling pattern, resulting in a marked
eduction in the ratio of E to A velocities (Table 1).
Table 2 also shows hemodynamic assessments for the
hree groups of rats at the 18th day after MI. No significant
ifference was noted in heart rate among the three groups.
ean arterial pressure and LV systolic pressure were lower
olume fraction in the remote and border noninfarcted left ventricular area
volume stained with Sirius red in the remote noninfarcted LV (200
mean  SEM. **p  0.01 compared with the sham-operated group; ##p
erroni multiple-comparison t test.
able 2. Hemodynamic Parameters
Sham MIVehicle MICNP
R, beats/min 412  5 421  6 410  5
AP, mm Hg 120  2 99  2* 103  2*
VSP, mm Hg 139  2 116  2* 118  2*
VEDP, mm Hg 7  0.4 18  1* 13  1*†
V dP/dtmax,
mm Hg/s
7,970  156 5,019  155* 5,743  155*†
V dP/dtmin,
mm Hg/s
6,216  158 3,791  151* 4,644  147*†
O, ml/min 98  2 73  2* 81  2*†
alues are mean  SEM. *p  0.01 compared with sham-operated group; †p  0.01
ompared with MIvehicle group by analysis of variance and Bonferroni multiple-
omparison t test.
CNP  C-type natriuretic peptide; CO  cardiac output; HR  heart rate; LV
P/dt max or min peak rate of left ventricular rise or fall; LVEDP left ventriculargen v
llagen
s arend-diastolic pressure; LVSP  left ventricular systolic pressure; MAP  mean
rterial pressure; MI  myocardial infarction.
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CNP and Cardiac Remodeling After MI February 15, 2005:608–16n the MIvehicle and MICNP groups than in sham, but
here were no differences in these parameters between the
wo MI groups. Left ventricular end-diastolic pressure was
igher, and the peak rate of contraction (dP/dtmax), the peak
ate of relaxation (dP/dtmin), and the cardiac output were
ower in MIvehicle than in sham. As shown in Table 2,
he MI-induced systolic and diastolic LV dysfunction was
arkedly improved by CNP.
he effect of CNP on cardiac collagen volume and
ypertrophy. To clarify the mechanism of improved car-
iac performance caused by CNP, we examined the effects
f CNP treatment on collagen volume and mural hypertro-
hy in the noninfarcted region; CNP significantly (p 
.01) attenuated an increase in morphometrical collagen
olume fraction in the remote LV (Fig. 2) and RV (sham:
.3  0.3%; MIvehicle: 5.5  0.5%; MICNP: 4.2 
.3%). Furthermore, CNP reduced an increase in collagen
olume fraction more effectively in the border region of MI,
n which fibrosis was more prominent compared with the
emote zone (Fig. 2).
The cross-sectional area and diameter of myocytes in the
oninfarcted LV significantly increased in MIvehicle
ompared with sham, and hypertrophy of the myocytes was
ignificantly (p  0.01) inhibited by CNP infusion (Fig. 3).
n agreement with the above results, the heart-weight-to-
igure 3. The effect of C-type natriuretic peptide (CNP) infusion
hotomicrographs of cardiomyocyte size stained with hematoxylin and
ardiomyocyte area and diameter (right). Values are mean  SEM. **p 
yocardial infarction (MI)  vehicle group by analysis of variance and Body-weight ratio, which was increased in the two MI proups compared with sham, was significantly (p  0.01)
owered by CNP treatment (sham: 3.29  0.03 g/kg;
Ivehicle: 3.96  0.09 g/kg; MICNP: 3.69  0.06
/kg).
he effect of CNP on gene expression. To confirm the
ffects of CNP on cardiac remodeling, we examined the
xpression of several mRNAs associated with fibrosis and
ypertrophy in the noninfarcted LV and RV after MI (Figs.
A, representative autoradiograms, and 4B, quantitative
nalysis, n  10 in each group). As shown in Figure 4, the
ncreased mRNA expression of collagen type I and collagen
ype III after MI was significantly suppressed by treatment
ith CNP. The increased fibronectin mRNA expression
ended to be decreased by CNP, but it was not significant.
t the 18th day, mRNA expression of TGF--1, which is
ell known to be a fibrotic cytokine and to be upregulated
n the acute phase of MI (15), was not different between MI
ats with or without CNP infusion; CNP treatment resulted
n suppression of the ANP mRNA level, which is a useful
arker of cardiac fetal phenotype modulation after MI, and
he -/-MHC ratio, which is a qualitative marker of
ardiac hypertrophy, in the noninfarcted LV (Fig. 4). In the
nfarcted LV, mRNA levels of collagen type I, collagen type
II, fibronectin, TGF--1, ANP, and -/-MHC were all
ncreased in the MIvehicle and MICNP groups com-
ardiac hypertrophy in the noninfarcted left ventricle. Representative
(400 magnification) (left) and quantitative morphometric analysis of
compared with the sham-operated group; ##p  0.01 compared with the
oni multiple-comparison t test.on c
eosin
0.01ared with sham, but there was no difference in these
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February 15, 2005:608–16 CNP and Cardiac Remodeling After MIarameters in the infarcted LV between the two MI groups
data not shown).
ellular mechanism of the antifibrotic action of
NP. C-type natriuretic peptide and 8-Bromo cGMP, an
nalog of cGMP, decreased the incorporation of [3H]pro-
ine into cardiac fibroblasts in a dose-dependent manner
Figs. 5A and 5B). The decrease of [3H]proline incorpora-
ion by CNP was completely blocked by Rp-8-pCPT-
GMP, a cell-permeable inhibitor of PKG type I and type
I, at a concentration of 105 mol/l (Fig. 5C).
ndogenous CNP expression after MI. C-type natri-
retic peptide mRNA expression increased on day 3 by
bout four-fold in the infarcted LV and two-fold in the
oninfarcted LV compared with sham rats, and gradually
ecreased from day 7 to day 18 (Fig. 6A). C-type natriuretic
eptide mRNA expression in RV slightly increased on day
only (1.5-fold) (Fig. 6A). In addition, immunohistochem-
cal study revealed that CNP was stained mainly in fibrotic
igure 4. The effect of C-type natriuretic peptide (CNP) on messenger
yocardial infarction (MI). (A) Typical autoradiograms of Northern blot
LV) for collagen type I, collagen type III, fibronectin, transforming grow
hain (MHC), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH
ene in the RV and noninfarcted LV at the 18th day after MI (n  10 i
APDH mRNA value. Levels in sham-operated rats were arbitrarily assig
ith the sham-operated group; #p  0.05 compared with the MIvehicle
ars  sham; striped bars  MIvehicle; solid bars  MICNP.rea of the infarct and border region on day 7 after MI (Fig. nB). These results suggest that endogenous local CNP
ight play an important role in the infarcted heart.
ISCUSSION
n this study, we have demonstrated that in vivo adminis-
ration of CNP improved cardiac function and protected
gainst cardiac remodeling after MI in rats. The beneficial
ffects of CNP treatment in the heart after MI included
ttenuation of cardiac fibrosis, hypertrophy, and LV en-
argement.
In addition, continuous treatment with CNP had no
ffects on mean arterial pressure and LV systolic pressure at
he time of sacrifice 18 days after MI. The serial change in
oninvasive blood pressure during the recovery period after
I was also similar in rats with and without CNP treat-
ent. These findings are consistent with previous studies,
hich showed that CNP infusion had little vasodepressor or
ucleic acid (mRNA) expression associated with cardiac remodeling after
is of mRNA levels in right ventricle (RV) and noninfarcted left ventricle
tor-(TGF)--1, atrial natriuretic peptide (ANP), - and -myosin heavy
e 18th day after MI. (B) Quantitative analyses of the abundance of each
group). In individual samples, each mRNA value was corrected for the
value of 1.0. Values are mean  SEM. **p  0.01, *p  0.05 compared
by analysis of variance and Bonferroni multiple-comparison t test. Openribon
analys
th fac
) at th
n each
ned a
groupatriuretic activities in rats and healthy humans (4,11).
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CNP and Cardiac Remodeling After MI February 15, 2005:608–16imilarly, the heart rate was not significantly affected by
NP infusion throughout the study period.
he effect of CNP on cardiac performance. Chronic
dministration of CNP improved cardiac performance in
I rats, as indicated by increases in LV fractional shorten-
ng, cardiac output, and LV dP/dtmax/min, and by decreases
n E/A ratio and LV end-diastolic pressure, which were
ccompanied by improvement of LV enlargement. Because
he effect of CNP on pre- or after-load, heart rate, and
nfarct size was very little, a mechanism other than hemo-
ynamic improvement or reduction in infarct size is prob-
bly the cause of the beneficial effects of CNP on cardiac
erformance.
he beneficial effect of CNP on cardiac remodeling
hrough its antifibrotic action. One possibility is that
igure 5. The effect of C-type natriuretic peptide (CNP) on collagen
ynthesis via the cyclic guanosine monophosphate (cGMP)/cyclic
uanosine monophosphate-dependent protein kinase (PKG) pathway in
ultured neonatal rat cardiac fibroblasts. (A and B) The effect of CNP and
-Bromo cGMP on [3H]proline incorporation in cardiac fibroblasts. (C)
3H]proline incorporation in the presence or absence of 108 mol/l CNP
ith or without Rp-8-pCPT-cGMP, PKG inhibitor. Values are mean 
EM. **p  0.01, *p  0.05 compared with control by analysis of variance
nd Bonferroni multiple-comparison t test.NP directly inhibits myocardial fibrosis because we have nreviously demonstrated that CNP directly inhibited both
NA and collagen synthesis by cardiac fibroblasts in vitro
6). In the present study, we have, therefore, examined the
n vivo effect of CNP on fibrosis and found that CNP
ignificantly attenuated an increase in morphometrical col-
agen volume fraction in the noninfarcted LV and RV. In
ddition, the effect of CNP was more prominent in the
order region of MI, in which fibrosis was more increased,
han that in the remote region. Because our preliminary
tudy showed that a number of fibroblasts shift toward a
yofibroblastic phenotype indicated by -smooth muscle
ctin in the border region of MI, CNP might have more
otent inhibitory effect on myofibroblast-like cells than on
broblasts. Furthermore, the mRNA levels of collagen type
and III in the noninfarcted LV and RV were suppressed by
reatment with CNP. These results provide in vivo evidence
hat CNP is a potent “fibrosis-inhibitory agent” after MI.
he amount of myocardial collagen deposition in the
nfarcted and noninfarcted regions during healing after MI
as reported to influence and to be integral to the process of
entricular remodeling (16). In addition, it has been shown
hat excessive accumulation of myocardial collagen might
esult in rigidity of the myocardium and severely impaired
elaxation (17). Therefore, improved LV dP/dtmax/min by
NP after MI might reflect improved myocardial rigidity in
he noninfarcted region caused by the reduction in cardiac
brosis.
Given the in vivo antifibrotic action of CNP, we further
xplored the cellular mechanisms of this action in vitro.
onsistent with our previous study (6), CNP or 8-Bromo
GMP, an analog of cGMP, potently inhibited collagen
ynthesis of cultured cardiac fibroblasts. In the present
tudy, the inhibitory effect of CNP was completely blocked
y Rp-8-pCPT-cGMP, an inhibitor of PKG (Fig. 5),
ndicating that CNP inhibited collagen synthesis by activat-
ng cGMP/PKG pathway.
Some experimental data suggest that antifibrotic agents
ould potentially enhance the remodeling of the extracellu-
ar collagen matrix in the infarct zone during very early stage
f healing after MI (18). However, in the present study, the
eath rate of the MICNP group (6%) was lower than that
f the MIvehicle group (17%) during the two-week
nfusion period, and two dead rats with CNP treatment
howed no findings of LV rupture. The late start of CNP
nfusion at the fourth day of MI might reduce the potential
dverse effects of antifibrosis such as wall thinning of infarct
one. Further studies are needed to determine the best
iming of CNP treatment after MI.
he beneficial effect of CNP on cardiac remodeling
hrough its antihypertrophic action. Another possible
echanism of cardioprotection by CNP might be attenu-
ted myocardial hypertrophy after MI. As shown in the
esults section, CNP effectively reduced the MI-induced
yocardial hypertrophy in vivo. The findings are in agree-
ent with previous in vitro studies, which showed that
atriuretic peptides including CNP prevented hypertrophy
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February 15, 2005:608–16 CNP and Cardiac Remodeling After MIf cultured cardiomyocytes (7,19). Although the precise
echanism by which CNP inhibits cardiac hypertrophy
emains unknown, our previous study (7) suggested that
NP inhibits hypertrophy of cardiac myocytes directly by
ctivating cGMP-dependent mechanism and indirectly by
educing endothelin-1 secretion from nonmyocytes.
On the other hand, because hypertrophy after MI is an
daptive response that offsets increased load, attenuates
rogressive dilation, and stabilizes contractile function (20),
ecreased cardiac hypertrophy shown in the present study
ight be caused by the indirect effect of CNP via decreased
V systolic wall stress. Further studies are needed to
etermine the contribution ratio of direct and indirect
ffects of CNP on cardiac hypertrophy.
omparison with other antiremodeling therapies after
I. A number of therapeutic approaches to limiting ven-
ricular remodeling in MI have been reported. These agents
nclude angiotensin-converting enzyme inhibitors, angio-
ensin II type 1 receptor blockers, -adrenergic blockers,
ldosterone antagonists, and matrix metalloproteinase in-
ibitors. Although a number of these other agents have been
iven orally and, in this regard, they have an advantage over
NP, CNP treatment has some advantages concerning
hort treatment period and fewer side effects. Actually, in
revious studies, it took more than four weeks for other
gents to attain similar reduction of collagen volume frac-
ion as two weeks treatment of CNP. Furthermore, these
ynthetic agents might cause harmful effects such as severe
ypotension by vasodilators (21) or musculoskeletal toxicity
y matrix metalloproteinase inhibitors (22). Because CNP
oes not affect blood pressure, it can be used in hemody-
igure 6. Endogenous C-type natriuretic peptide (CNP) expressions after
nfarcted left ventricle (LV), noninfarcted LV, and right ventricle (RV) at
EM. **p  0.01, *p  0.05 compared with sham by analysis of variance an
NP expression. Upper photomicrographs show the section on day 7 afte
y antifibronectin antibody (right, red). Lower photomicrograph shows the
ehydrogenase.amically unstable patients as often seen in acute MI.tudy limitations. Because the effects of CNP were eval-
ated after two weeks of therapy in the present study, its
ong-term effects on the cardiac remodeling after MI remain
nclear. For future clinical application, further study is
ecessary to examine if the antiremodeling effects of CNP
ersist for the long-term follow-up period.
ummary. Our study has demonstrated that continuous
dministration of CNP improved LV dysfunction and
ttenuated the development of cardiac remodeling after MI.
ecause CNP has much weaker vasorelaxant and natriuretic
ctivities, but has much more potent antifibrotic and anti-
ypertrophic actions than ANP or BNP, these beneficial
ffects of CNP might be associated with direct effects on the
ailing heart. In conclusion, CNP is potentially useful as a
ew antiremodeling agent through its novel mechanism of
ction.
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